PharmTech Drug Digest 11.20
News|Articles|January 22, 2015

BASF Announces Plans to Expand PVP Facilities

BASF announced that it would invest $65 million to improve its PVP manufacturing facilities, as well as add production to its Shanghai facility.

 

BASF announced on Jan. 22, 2015 that it planned to invest up to €56 million ($65 million USD) in the expansion of its Polyvinyl pyrrolidone (PVP) value chain over the course of the next four years. PVP is a polymer used in the pharmaceutical industry because of its binding properties. The expansion will allow BASF to increase production by 6000 metric tons with improvements to facilities in Ludwigshafen, Germany and Geismar, Louisiana, USA, as well as adding the technology to produce PVP at its Shanghai, China facility.

PVP is a water-soluble polymer that can absorb large quantities of water;, it is temperature-resistant, pH-stable, non-ionic, and colorless. The binding abilities of BASF’s line of PVP products, called Kollidon, enable individual active ingredients of a tablet to form a homogenous entity and as a disintegrant it ensires ensures that the tablets break up in liquid and release the active ingredient quickly.

“With this investment, we are actively participating in the strongly growing PVP market, especially within the pharmaceutical industry,” said Saori Dubourg, president of BASF’s nutrition and health division, in a press release.

Source: BASF


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.